Potentiation of Halogenated Pyrimidine Radiosensitizers in Human Carcinoma Cells by β-Lapachone (3,4-dihydro-2,2-dimethyl-2h-naphtho[l,2-b]pyran-5,6-dione), a Novel DNA Repair Inhibitor

David A. Boothman, Sheldon Greer, Arthur B. Pardee

Research output: Contribution to journalArticle

Abstract

3,4-Dihydro-2,2-dimethyl-2H-naptho(l,2,-£]pyran-5,6-dione (β-lapa-chone) is a novel DNA repair inhibitor. It was tested for synergistic X-ray-induced lethality in combination with several halogenated pyrimidine radiosensitizers. Logarithmic-phase growing human epidermoid laryngeal carcinoma (hep-2) cells were allowed to incorporate pyrimidine analogues for 48 h (approximately two cell doublings) and then were X-irradiated and subjected to various posttreatments. β-Lapachone synergistically increased the dose enhancement ratios (DERs) of all analogues screened, with the exception of the 2’-chloro derivative of 5-bromode-oxyuridine. For example, following 5-bromodeoxycytidine sensitization an X-ray DER value of 1.87 ± 0.04 at 1% survival was increased to 3.51 ± 0.42 due to a 4-h post-X-irradiadon exposure to 4 μM β-lapachone. D0and D, values for halogenated pyrimidine-sensitized human epidermoid laryngeal carcinoma cells were decreased 1.4- to 5.4-fold and 1.4- to 4.0-fold, respectively. β-Lapachone had little effect upon the cytotoxicities of unirradiated human epidermoid laryngeal carcinoma cells whether or not they were previously exposed to any of the halogenated pyrimidine radiosensitizers. β-Lapachone treatment following X-irradiation of cells that had not incorporated a pyrimidine analogue exhibited DER values of 138 ± 0.05 and 1.40 ± 0.01 at 10 and 1% survival levels, respectively. β-Lapachone enhanced the radiosensitization of deoxycytidine analogues to a greater extent than the structurally related deoxyuridine analogues. Greater DERs and lower Do and Dq values were found for deoxycytidine than for deoxyuridine analogue radiosensitizers following 0-lapachone treatment. This agent may improve presently used radiation therapies and enhance proposed strategies which utilize deoxycytidine analogue radiosensitization together with protection of normal tissues by tetrahydrouridine to achieve tumor-selective radiotherapy.

Original languageEnglish (US)
Pages (from-to)5401-5406
Number of pages6
JournalCancer Research
Volume47
Issue number20
StatePublished - 1987

Fingerprint

Pyrans
DNA Repair
Deoxycytidine
Carcinoma
Squamous Cell Carcinoma
Deoxyuridine
Bromodeoxycytidine
Tetrahydrouridine
Radiotherapy
X-Rays
Survival
pyrimidine
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Potentiation of Halogenated Pyrimidine Radiosensitizers in Human Carcinoma Cells by β-Lapachone (3,4-dihydro-2,2-dimethyl-2h-naphtho[l,2-b]pyran-5,6-dione), a Novel DNA Repair Inhibitor. / Boothman, David A.; Greer, Sheldon; Pardee, Arthur B.

In: Cancer Research, Vol. 47, No. 20, 1987, p. 5401-5406.

Research output: Contribution to journalArticle

@article{a45eaf7bda3d4c2eafc2a65ebf93f21f,
title = "Potentiation of Halogenated Pyrimidine Radiosensitizers in Human Carcinoma Cells by β-Lapachone (3,4-dihydro-2,2-dimethyl-2h-naphtho[l,2-b]pyran-5,6-dione), a Novel DNA Repair Inhibitor",
abstract = "3,4-Dihydro-2,2-dimethyl-2H-naptho(l,2,-£]pyran-5,6-dione (β-lapa-chone) is a novel DNA repair inhibitor. It was tested for synergistic X-ray-induced lethality in combination with several halogenated pyrimidine radiosensitizers. Logarithmic-phase growing human epidermoid laryngeal carcinoma (hep-2) cells were allowed to incorporate pyrimidine analogues for 48 h (approximately two cell doublings) and then were X-irradiated and subjected to various posttreatments. β-Lapachone synergistically increased the dose enhancement ratios (DERs) of all analogues screened, with the exception of the 2’-chloro derivative of 5-bromode-oxyuridine. For example, following 5-bromodeoxycytidine sensitization an X-ray DER value of 1.87 ± 0.04 at 1{\%} survival was increased to 3.51 ± 0.42 due to a 4-h post-X-irradiadon exposure to 4 μM β-lapachone. D0and D, values for halogenated pyrimidine-sensitized human epidermoid laryngeal carcinoma cells were decreased 1.4- to 5.4-fold and 1.4- to 4.0-fold, respectively. β-Lapachone had little effect upon the cytotoxicities of unirradiated human epidermoid laryngeal carcinoma cells whether or not they were previously exposed to any of the halogenated pyrimidine radiosensitizers. β-Lapachone treatment following X-irradiation of cells that had not incorporated a pyrimidine analogue exhibited DER values of 138 ± 0.05 and 1.40 ± 0.01 at 10 and 1{\%} survival levels, respectively. β-Lapachone enhanced the radiosensitization of deoxycytidine analogues to a greater extent than the structurally related deoxyuridine analogues. Greater DERs and lower Do and Dq values were found for deoxycytidine than for deoxyuridine analogue radiosensitizers following 0-lapachone treatment. This agent may improve presently used radiation therapies and enhance proposed strategies which utilize deoxycytidine analogue radiosensitization together with protection of normal tissues by tetrahydrouridine to achieve tumor-selective radiotherapy.",
author = "Boothman, {David A.} and Sheldon Greer and Pardee, {Arthur B.}",
year = "1987",
language = "English (US)",
volume = "47",
pages = "5401--5406",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Potentiation of Halogenated Pyrimidine Radiosensitizers in Human Carcinoma Cells by β-Lapachone (3,4-dihydro-2,2-dimethyl-2h-naphtho[l,2-b]pyran-5,6-dione), a Novel DNA Repair Inhibitor

AU - Boothman, David A.

AU - Greer, Sheldon

AU - Pardee, Arthur B.

PY - 1987

Y1 - 1987

N2 - 3,4-Dihydro-2,2-dimethyl-2H-naptho(l,2,-£]pyran-5,6-dione (β-lapa-chone) is a novel DNA repair inhibitor. It was tested for synergistic X-ray-induced lethality in combination with several halogenated pyrimidine radiosensitizers. Logarithmic-phase growing human epidermoid laryngeal carcinoma (hep-2) cells were allowed to incorporate pyrimidine analogues for 48 h (approximately two cell doublings) and then were X-irradiated and subjected to various posttreatments. β-Lapachone synergistically increased the dose enhancement ratios (DERs) of all analogues screened, with the exception of the 2’-chloro derivative of 5-bromode-oxyuridine. For example, following 5-bromodeoxycytidine sensitization an X-ray DER value of 1.87 ± 0.04 at 1% survival was increased to 3.51 ± 0.42 due to a 4-h post-X-irradiadon exposure to 4 μM β-lapachone. D0and D, values for halogenated pyrimidine-sensitized human epidermoid laryngeal carcinoma cells were decreased 1.4- to 5.4-fold and 1.4- to 4.0-fold, respectively. β-Lapachone had little effect upon the cytotoxicities of unirradiated human epidermoid laryngeal carcinoma cells whether or not they were previously exposed to any of the halogenated pyrimidine radiosensitizers. β-Lapachone treatment following X-irradiation of cells that had not incorporated a pyrimidine analogue exhibited DER values of 138 ± 0.05 and 1.40 ± 0.01 at 10 and 1% survival levels, respectively. β-Lapachone enhanced the radiosensitization of deoxycytidine analogues to a greater extent than the structurally related deoxyuridine analogues. Greater DERs and lower Do and Dq values were found for deoxycytidine than for deoxyuridine analogue radiosensitizers following 0-lapachone treatment. This agent may improve presently used radiation therapies and enhance proposed strategies which utilize deoxycytidine analogue radiosensitization together with protection of normal tissues by tetrahydrouridine to achieve tumor-selective radiotherapy.

AB - 3,4-Dihydro-2,2-dimethyl-2H-naptho(l,2,-£]pyran-5,6-dione (β-lapa-chone) is a novel DNA repair inhibitor. It was tested for synergistic X-ray-induced lethality in combination with several halogenated pyrimidine radiosensitizers. Logarithmic-phase growing human epidermoid laryngeal carcinoma (hep-2) cells were allowed to incorporate pyrimidine analogues for 48 h (approximately two cell doublings) and then were X-irradiated and subjected to various posttreatments. β-Lapachone synergistically increased the dose enhancement ratios (DERs) of all analogues screened, with the exception of the 2’-chloro derivative of 5-bromode-oxyuridine. For example, following 5-bromodeoxycytidine sensitization an X-ray DER value of 1.87 ± 0.04 at 1% survival was increased to 3.51 ± 0.42 due to a 4-h post-X-irradiadon exposure to 4 μM β-lapachone. D0and D, values for halogenated pyrimidine-sensitized human epidermoid laryngeal carcinoma cells were decreased 1.4- to 5.4-fold and 1.4- to 4.0-fold, respectively. β-Lapachone had little effect upon the cytotoxicities of unirradiated human epidermoid laryngeal carcinoma cells whether or not they were previously exposed to any of the halogenated pyrimidine radiosensitizers. β-Lapachone treatment following X-irradiation of cells that had not incorporated a pyrimidine analogue exhibited DER values of 138 ± 0.05 and 1.40 ± 0.01 at 10 and 1% survival levels, respectively. β-Lapachone enhanced the radiosensitization of deoxycytidine analogues to a greater extent than the structurally related deoxyuridine analogues. Greater DERs and lower Do and Dq values were found for deoxycytidine than for deoxyuridine analogue radiosensitizers following 0-lapachone treatment. This agent may improve presently used radiation therapies and enhance proposed strategies which utilize deoxycytidine analogue radiosensitization together with protection of normal tissues by tetrahydrouridine to achieve tumor-selective radiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84965817278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965817278&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84965817278

VL - 47

SP - 5401

EP - 5406

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 20

ER -